Prot #POLARIS2022-001: ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial

Project: Research project

Project Details

StatusActive
Effective start/end date4/30/24 → 4/30/27

Funding

  • Polaris Pharmaceuticals, Inc. (Prot #POLARIS2022-001)